Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT01596088

A Phase I/II Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents

A Multicenter, Open Label, Single-arm Study of KDX-0811(Dexrazoxane) in the Treatment of Accidental Extravasation of Anthracycline Anti-cancer Agents

Sponsor: Kissei Pharmaceutical Co., Ltd.

Conditions Extravasations of Anthracycline Anti-cancer Agents

Interventions Dexrazoxane

Updated 7 times since 2017 Last updated: Mar 18, 2015 Primary completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Extravasations of Anthracycline Anti-cancer Agents, this trial is completed. The trial is conducted by Kissei Pharmaceutical Co., Ltd. and has accumulated 7 data snapshots since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kissei Pharmaceutical Co., Ltd.

Data source: Kissei Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo and Other Japanese City, Japan